Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure

Molecular Therapy

Volumn 22, Issue 12, 2014, Pages 2038-2045

  Ishikawa, Kiyotake ^a   Fish, Kenneth M ^a   Tilemann, Lisa ^a   Rapti, Kleopatra ^a   Aguero, Jaume ^a   Santos Gallego, Carlos G ^a   Lee, Ahyoung ^a   Karakikes, Ioannis ^a   Xie, Chaoqin ^a   Akar, Fadi G ^a   Shimada, Yuichi J ^b   Gwathmey, Judith K ^c   Asokan, Aravind ^d   McPhee, Scott ^e   Samulski, Jade ^e   Samulski, Richard Jude ^d   Sigg, Daniel C ^f   Weber, Thomas ^a   Kranias, Evangelia G ^g   Hajjar, Roger J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c Gwathmey Inc   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e ASKLEPIOS BIOPHARMACEUTICAL INC   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; INHIBITOR 1C PROTEIN; PARVOVIRUS VECTOR; SODIUM CHLORIDE; UNCLASSIFIED DRUG; PHOSPHOPROTEIN PHOSPHATASE 1;

ADENO ASSOCIATED VIRUS 2; ADENO ASSOCIATED VIRUS 8; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOENGINEERING; CARDIOVASCULAR GENE THERAPY; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DRUG SYNTHESIS; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART PERFORMANCE; HEART PRELOAD; HEART STROKE VOLUME; HEART WORK; HUMAN; HUMAN CELL; LOW DRUG DOSE; NONHUMAN; PRESSURE VOLUME CURVE; TRANSGENE; TREATMENT RESPONSE; VIRUS CAPSID; VIRUS GENOME; YORKSHIRE PIG; ADMINISTRATION AND DOSAGE; ANIMAL; CLASSIFICATION; DEPENDOPARVOVIRUS; DISEASE MODEL; ENZYMOLOGY; GENE THERAPY; GENE VECTOR; GENETICS; INTRAARTERIAL DRUG ADMINISTRATION; METABOLISM; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PIG;

ADENO-ASSOCIATED VIRUS; MIRIDAE; SUIDAE;

ANIMALS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GENETIC VECTORS; HEART FAILURE; HUMANS; INJECTIONS, INTRA-ARTERIAL; MYOCARDIAL INFARCTION; PROTEIN PHOSPHATASE 1; STROKE VOLUME; SWINE;

EID: 84927132551     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.127     Document Type: Article

References (34)

1. Roger, VL, Go, AS, Lloyd-Jones, DM, Benjamin, EJ, Berry, JD, Borden, WB et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. (2012). Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 125: e2-e220.
2. Ishikawa, K, Tilemann, L, Ladage, D, Aguero, J, Leonardson, L, Fish, K et al. (2012). Cardiac gene therapy in large animals: bridge from bench to bedside. Gene Ther 19: 670-677.
3. Jessup, M, Greenberg, B, Mancini, D, Cappola, T, Pauly, DF, Jaski, B et al.; Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators. (2011). Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 124: 304-313.
4. Hajjar, RJ (2013). Potential of gene therapy as a treatment for heart failure. J Clin Invest 123: 53-61.
5. Pacak, CA and Byrne, BJ (2011). AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities. Mol Ther 19: 1582-1590.
6. Calcedo, R, Vandenberghe, LH, Gao, G, Lin, J and Wilson, JM (2009). Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 199: 381-390.
7. Asokan, A (2010). Reengineered AAV vectors: old dog, new tricks. Discov Med 9: 399-403.
8. Asokan, A, Conway, JC, Phillips, JL, Li, C, Hegge, J, Sinnott, R et al. (2010). Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol 28: 79-82.
9. Kranias, EG and Hajjar, RJ (2012). Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circ Res 110: 1646-1660.
10. Kawase, Y and Hajjar, RJ (2008). The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases. Nat Clin Pract Cardiovasc Med 5: 554-565.
11. Fish, KM, Ladage, D, Kawase, Y, Karakikes, I, Jeong, D, Ly, H et al. (2013). AAV9.I-1c delivered via direct coronary infusion in a porcine model of heart failure improves contractility and mitigates adverse remodeling. Circ Heart Fail 6: 310-317.
12. Nicolaou, P, Hajjar, RJ and Kranias, EG (2009). Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology. J Mol Cell Cardiol 47: 365-371.
13. Wittkpper, K, Dobrev, D, Eschenhagen, T and El-Armouche, A (2011). Phosphatase-1 inhibitor-1 in physiological and pathological -adrenoceptor signalling. Cardiovasc Res 91: 392-401.
14. Gupta, RC, Mishra, S, Rastogi, S, Imai, M, Habib, O and Sabbah, HN (2003). Cardiac SR-coupled PP1 activity and expression are increased and inhibitor 1 protein expression is decreased in failing hearts. Am J Physiol Heart Circ Physiol 285: H2373-H2381.
15. Carr, AN, Schmidt, AG, Suzuki, Y, del Monte, F, Sato, Y, Lanner, C et al. (2002). Type 1 phosphatase, a negative regulator of cardiac function. Mol Cell Biol 22: 4124-4135.
16. El-Armouche, A, Pamminger, T, Ditz, D, Zolk, O and Eschenhagen, T (2004). Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts. Cardiovasc Res 61: 87-93.
17. El-Armouche, A, Wittkpper, K, Degenhardt, F, Weinberger, F, Didi, M, Melnychenko, I et al. (2008). Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy. Cardiovasc Res 80: 396-406.
18. Sahin, B, Shu, H, Fernandez, J, El-Armouche, A, Molkentin, JD, Nairn, AC et al. (2006). Phosphorylation of protein phosphatase inhibitor-1 by protein kinase C. J Biol Chem 281: 24322-24335.
19. Rodriguez, P, Mitton, B, Waggoner, JR and Kranias, EG (2006). Identification of a novel phosphorylation site in protein phosphatase inhibitor-1 as a negative regulator of cardiac function. J Biol Chem 281: 38599-38608.
20. Pathak, A, del Monte, F, Zhao, W, Schultz, JE, Lorenz, JN, Bodi, I et al. (2005). Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res 96: 756-766.
21. Chen, G, Zhou, X, Florea, S, Qian, J, Cai, W, Zhang, Z et al. (2010). Expression of active protein phosphatase 1 inhibitor-1 attenuates chronic beta-agonist-induced cardiac apoptosis. Basic Res Cardiol 105: 573-581.
22. Nicolaou, P, Rodriguez, P, Ren, X, Zhou, X, Qian, J, Sadayappan, S et al. (2009). Inducible expression of active protein phosphatase-1 inhibitor-1 enhances basal cardiac function and protects against ischemia/reperfusion injury. Circ Res 104: 1012-1020.
23. Kass, DA, Maughan, WL, Guo, ZM, Kono, A, Sunagawa, K and Sagawa, K (1987). Comparative influence of load versus inotropic states on indexes of ventricular contractility: experimental and theoretical analysis based on pressure-volume relationships. Circulation 76: 1422-1436.
24. Little, WC, Cheng, CP, Mumma, M, Igarashi, Y, Vinten-Johansen, J and Johnston, WE (1989). Comparison of measures of left ventricular contractile performance derived from pressure-volume loops in conscious dogs. Circulation 80: 1378-1387.
25. Zhong, L, Li, B, Mah, CS, Govindasamy, L, Agbandje-McKenna, M, Cooper, M et al. (2008). Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA 105: 7827-7832.
26. Bowles, DE, McPhee, SW, Li, C, Gray, SJ, Samulski, JJ, Camp, AS et al. (2012). Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther 20: 443-455.
27. Bish, LT, Morine, K, Sleeper, MM, Sanmiguel, J, Wu, D, Gao, G et al. (2008). Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther 19: 1359-1368.
28. Inagaki, K, Fuess, S, Storm, TA, Gibson, GA, Mctiernan, CF, Kay, MA et al. (2006). Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 14: 45-53.
29. Jaski, BE, Jessup, ML, Mancini, DM, Cappola, TP, Pauly, DF, Greenberg, B et al.; Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID) Trial Investigators. (2009). Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase clinical trial. J Card Fail 15: 171-181.
30. Grieger, JC, Choi, VW and Samulski, RJ (2006). Production and characterization of adeno-associated viral vectors. Nat Protoc 1: 1412-1428.
31. Ishikawa, K, Chemaly, ER, Tilemann, L, Fish, K, Ladage, D, Aguero, J et al. (2012). Assessing left ventricular systolic dysfunction after myocardial infarction: are ejection fraction and dP/dt(max) complementary or redundant? Am J Physiol Heart Circ Physiol 302: H1423-H1428.
32. Karakikes, I, Hadri, L, Rapti, K, Ladage, D, Ishikawa, K, Tilemann, L et al. (2012). Concomitant intravenous nitroglycerin with intracoronary delivery of AAV1.SERCA2a enhances gene transfer in porcine hearts. Mol Ther 20: 565-571.
33. Ishikawa, K, Ladage, D, Tilemann, L, Fish, K, Kawase, Y and Hajjar, RJ (2011). Gene transfer for ischemic heart failure in a preclinical model. J Vis Exp.
34. Rapti, K, Louis-Jeune, V, Kohlbrenner, E, Ishikawa, K, Ladage, D, Zolotukhin, S et al. (2012). Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol Ther 20: 73-83.